company background image
KYKO.F logo

Kyowa Kirin OTCPK:KYKO.F Stock Report

Last Price

US$18.10

Market Cap

US$9.6b

7D

-6.9%

1Y

n/a

Updated

28 Mar, 2024

Data

Company Financials +

Kyowa Kirin Co., Ltd.

OTCPK:KYKO.F Stock Report

Market Cap: US$9.6b

KYKO.F Stock Overview

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally.

KYKO.F fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance5/6
Financial Health6/6
Dividends5/6

Kyowa Kirin Co., Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kyowa Kirin
Historical stock prices
Current Share PriceJP¥18.10
52 Week HighJP¥22.67
52 Week LowJP¥15.78
Beta0.20
1 Month Change12.97%
3 Month Change8.06%
1 Year Changen/a
3 Year Changen/a
5 Year Change-15.02%
Change since IPO235.15%

Recent News & Updates

Recent updates

Shareholder Returns

KYKO.FUS PharmaceuticalsUS Market
7D-6.9%1.2%0.4%
1Yn/a25.8%28.8%

Return vs Industry: Insufficient data to determine how KYKO.F performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how KYKO.F performed against the US Market.

Price Volatility

Is KYKO.F's price volatile compared to industry and market?
KYKO.F volatility
KYKO.F Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: KYKO.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine KYKO.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19495,974Masashi Miyamotohttps://www.kyowakirin.com

Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, marketing, and import/export of pharmaceuticals for oncology, nephrology, central nervous system, and immunology therapeutic areas in Japan, the United States, rest of the Americas, Europe, Asia, and internationally. Its products include ALLELOCK, an antihistamine agent for patients with various types of allergies; CONIEL, a calcium channel blocker for hypertension and angina pectoris; Crysvita, a recombinant human monoclonal IgG1 antibody against the phosphaturic hormone fibroblast growth factor 23; ESPO, a glycoprotein and human erythropoietin; NESP, an erythropoiesis stimulating agent; and GRAN, a human colony-stimulating factor. The company also develops GRAN /Peglasta/Neulasta for chemotherapy-induced febrile neutropenia; LUMICEF, a biological treatment for moderate to severe plaque psoriasis; Moventig, a mu-opioid receptor antagonist for the treatment of opioid induced constipation; Nouriast/ Nourianz, an adenosine receptor antagonist for Parkinson’s disease; and ORKEDIA, an oral calcimimetics agent.

Kyowa Kirin Co., Ltd. Fundamentals Summary

How do Kyowa Kirin's earnings and revenue compare to its market cap?
KYKO.F fundamental statistics
Market capUS$9.62b
Earnings (TTM)US$536.46m
Revenue (TTM)US$2.92b

17.9x

P/E Ratio

3.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
KYKO.F income statement (TTM)
RevenueJP¥442.23b
Cost of RevenueJP¥111.21b
Gross ProfitJP¥331.03b
Other ExpensesJP¥249.84b
EarningsJP¥81.19b

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 07, 2024

Earnings per share (EPS)151.35
Gross Margin74.85%
Net Profit Margin18.36%
Debt/Equity Ratio0%

How did KYKO.F perform over the long term?

See historical performance and comparison

Dividends

2.1%

Current Dividend Yield

37%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.